NovoCure's Q1 beat, Optune Lua momentum, and global expansion signal strong growth ahead. Find out why NVCR stock is a buy.

As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running ...

NeoGenomics has commercially launched the c-MET Companion Diagnostic (CDx) for use in non-small cell lung cancer (NSCLC), ...

The FDA has approved Emrelis for the treatment of adult patients with locally advanced or metastatic NSCLC with high c-Met protein overexpression.

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990 ...

Eligible patients with previously untreated, metastatic squamous non–small-cell lung cancer (NSCLC) were randomly assigned ... metastatic squamous NSCLC and is a standard-of-care first-line treatment ...

Older adults with advanced lung cancer pose unique challenges to care, including multiple chronic condition, polypharmacy, and geriatric syndromes. Fit individuals clearly benefit from standard ...

Data will be shared in two oral presentations, a poster and two online abstractsHighlights include a potential novel, ...

One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20%. Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advan ...

Preliminary results from a different ongoing study suggest that the VeriStrat test may have similar indications in patients with other types of solid tumors. Data from this study is expected to be ...

David P. Carbone, MD, PhD, discusses the outcomes of the phase 3 CheckMate 9LA trial in non–small cell lung cancer based on treatment discontinuation.

Earlier this year, Cullinan said its lead candidate hit the bull's-eye in a midstage lung cancer cancer trial but stayed mum ...